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Inhibition of NF-jB Signaling Retards Eosinophilic
Dermatitis in SHARPIN-Deficient Mice
Yanhua Liang1, Rosemarie E. Seymour1 and John P. Sundberg1
The NF-kB pathway performs pivotal roles in diverse physiological processes such as immunity, inflammation,
proliferation, and apoptosis. NF-kB is kept inactive in the cytoplasm through association with inhibitors (IkB),
and translocates to the nucleus to activate its target genes after the IkBs are phosphorylated and degraded.
Here, we demonstrate that loss of function of SHANK-associated RH domain interacting protein (SHARPIN)
leads to activation of NF-kB signaling in skin, resulting in the development of an idiopathic hypereosinophilic
syndrome (IHES) with eosinophilic dermatitis in C57BL/KaLawRij-Sharpincpdm/RijSunJ mice, and clonal
expansion of B-1 B cells and CD3þCD4CD8 T cells. Transcription profiling in skin revealed constitutive
activation of classical NF-kB pathways, predominantly by overexpressed members of IL1 family. Compound-null
mutants for both the IL1 receptor accessory protein (Il1raptm1Roml) and SHARPIN (Sharpincpdm) resulted in mice
having decreased skin disease severity. Inhibition of IkBA degradation by the proteasome inhibitor bortezomib
alleviated the dermatitis in Sharpincpdm mice. These results indicate that absence of SHARPIN causes IHES
with eosinophilic dermatitis by NF-kB activation, and bortezomib may be an effective treatment for skin
problems of IHES.
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INTRODUCTION
Hypereosinophilic syndromes (HESs) are a rare, heteroge-
neous group of hematological and systemic diseases
characterized by unexplained blood and tissue eosinophilia,
either mediated by extrinsic cytokines or as a consequence of
intrinsic mutations in hematopoietic stem cells, leading to
predominantly eosinophil differentiation (Leiferman, 1995;
Fletcher and Bain, 2007; Roufosse et al., 2007; Kahn et al.,
2008; Sheikh and Weller, 2009). Eosinophilic infiltration into
multiple tissues and eosinophilia are the prominent features of
chronic proliferative dermatitis mutation (CPDM) in mouse,
due to a spontaneous null mutation in the SHANK-associated
RH domain interacting protein (Sharpin) gene (HogenEsch
et al., 1993; Gijbels et al., 1995; Seymour et al., 2007). These
mutant mice were initially recognized by the erythematous
phenotype, that is, scaly areas of alopecia due to marked
epidermal hyperplasia and dermal granulocytic infiltration.
The molecular mechanism that caused the severe phenotype
seen in Sharpincpdm/Sharpincpdm mice was unknown because
of the limited understanding of the biological function(s) of the
Sharpin gene (Lim et al., 2001; Daigo et al., 2003).
The NF-kB signaling pathway serves a crucial role in
regulating the transcriptional responses of multifunctional
physiological processes that include cell division,
cell survival, differentiation, immunity, and inflammation
(Gerondakis et al., 2006; Gilmore, 2006). It can induce
different kinetic or phenotypic properties in various cell types
or even in the same clonal cell population in other cellular
environments (Mercurio and Manning, 1999; Pasparakis
et al., 2006). Dysregulation of the NF-kB pathway is involved
in many diseases, particularly ones associated with chronic
inflammation, immunodeficiency, or cancer (Aradhya and
Nelson, 2001; Baldwin, 2001; Courtois, 2005; Courtois and
Gilmore, 2006). NF-kB is expressed in the cytoplasm of
virtually all cell types, wherein its activity is controlled by
inhibitors of NF-kB (IkBs) (Hayden and Ghosh, 2004). In the
classical NF-kB pathway, binding of ligands (for example,
tumor necrosis factor (TNF), IL1) to their receptors (TNFR,
IL1R) triggers polyubiquitination of factors such as TNF
receptor-associated factors (for example, TRAF2, TRAF6),
leading to phosphorylation, ubiquitination, and degradation of
IkBs. In the alternative pathway, NF-kB2/p100 is phosphory-
lated by the conserved helix–loop–helix ubiquitous kinase
(CHUK) and then polyubiquitinated. Proteolysis of the carbox-
yl-terminal of p100 follows, and the RELB/p52 transcription
factor is released. In both classical and alternative pathways,
translocation of NF-kB also induces transcription of IkBs,
which in turn bind to nuclear NF-kB and export it back into the
cytosol as a negative feedback circuit (Kim et al., 2009).
The yeast two-hybrid screen with TRAF2 as the bait (UCSD
Nature Signaling Gateway; http://www.signaling-gateway.org)
identified SHARPIN (alternative symbol: protein kinase
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C-interacting protein RBCC-like 1 (RBCKL1)) as one of its
prey in B cell lines, indicating that SHARPIN may interact
with TRAF2 to regulate activation of NF-kB signaling.
A series of functional studies were conducted to dissect the
molecular mechanism of eosinophilic dermatitis seen in
Sharpincpdm/Sharpincpdm-mutant mice and shed light on
similar human diseases.
RESULTS
Phenotype of idiopathic HES in Sharpincpdm/Sharpincpdm mice
The Sharpincpdm/Sharpincpdm-mutant mouse was first repor-
ted as having chronic, severe, and mixed granulocytic
inflammation with epidermal hyperproliferation and puritic,
scaly, and ulcerated cutaneous lesions (HogenEsch et al.,
1993; Gijbels et al., 1996). Many visceral organs are affected
and characterized by mixed granulocytic, primarily eosino-
philic infiltration, which makes chronic proliferative derma-
titis in mice an eosinophilic disorder (Simon and Simon,
2007). To further address which eosinophilic disorder
Sharpincpdm/Sharpincpdm mimics, specific parameters for
several known human eosinophilic diseases were tested.
Hematological counting identified eosinophilia of
2,685±56, 1,770±65, 1,040±34, 1,230±44 eosinophils
per ml in mutant (Sharpincpdm/Sharpincpdm) mice compared
with 250±35, 150±55, 200±70, 160±42 eosinophils
per ml in þ /þ mice, respectively, at the age of 4, 6, 8, and
10 weeks. The eosinophil counts in the peripheral blood of
þ /þ mouse are in the range of that in humans (0–350cells
per ml) (Rothenberg, 1998). Persistent and marked eosino-
philia, lack of other associations with eosinophilia (such as
infectious diseases and allergic diseases), and systemic
eosinophilic inflammation suggests that Sharpincpdm/
Sharpincpdm-mutant mice represent a mouse model for one or
more of the human idiopathic HESs (IHESs) (Leiferman, 1995).
To further determine whether the Sharpincpdm/Sharpincpdm
mice mimic the lymphocytic variant of HESs, fluorescence-
activated cell sorting (FACS) analysis was performed using
splenocytes. The wet weight of spleens of Sharpincpdm/
Sharpincpdm mice (0.2±0.01 g) was approximately three
times of that of þ /þ mice (0.07±0.01 g). The percentage
of B cells, T cells, and dendritic cells were decreased in the
mutant mouse spleens. However, normalization by spleen
wet weight significantly altered these numbers (Supplemen-
tary Table S1 online). The B-1 B cells (CD45RþCD11bþ ) had
the greatest increase in Sharpincpdm/Sharpincpdm-mutant
mice, either before or after normalization. The percentage
of inflammatory cells (eosinophils, macrophages, monocytes,
and polymorphonuclear leukocytes) was also significantly
increased. CD3þCD4þ helper T cells and CD3þCD8þ
cytotoxic T cells were not significantly different from those
of controls after normalization, but both percentage and
total counts of CD3þCD4CD8 T cells were significantly
increased in Sharpincpdm/Sharpincpdm-mutant mice
(Supplementary Table S2 online). CD3CD4þ T cells were
also detected in Sharpincpdm/Sharpincpdm-mutants, but
this number was not as significant as that in human HES
patients (Supplementary Figure S1 online) (Simon et al., 1999).
Activated NF-jB signaling revealed by gene expression arrays
and confirmed by immunohistochemistry
A longitudinal transcriptome analysis of dorsal skin from
Sharpincpdm/Sharpincpdm-mutant mice compared with age-
and gender-matched þ /þ mice at 2, 4, 6, 8, and 10 weeks
of age was done using Ingenuity Pathway Analysis software
(Ingenuity Systems, http://www.ingenuity.com). Analysis of
the 2-week group identified downregulation of Sharpin and
upregulation of IL1 family, member 6 (Il1f6), stefin A3 (Stfa3),
complement component 3 (C3), and serine peptidase
inhibitor clade A member 3N (Serpina3n) with a q-value
below 0.05, which represented the earliest molecular
changes in the skin of these mutant mice. This concurs with
essentially no histological abnormalities in the skin of mutant
mice at this age. Pathway analysis revealed that NF-kB
signaling was the most significantly upregulated pathway
along with disease development (Figure 1). Most of the genes
in the NF-kB pathway (Nishikori, 2005) are progressively
upregulated in the skin of Sharpincpdm/Sharpincpdm-mutant
mice (Figure 2, Supplementary Figure S2 online) and IL1
pathway members, especially Il1f6, Il1f8, and Il1f9, are
most dramatically upregulated (Po0.0001), suggesting the
contributing role of Il1 stimuli for NF-kB activation. NF-kB
activation was validated by immunohistochemical localiza-
tion of phosphorylation of NF-kB p65 in skin of Sharpincpdm/
Sharpincpdm mice (Figure 3a) compared with that in control
mice (Figure 3b). Interaction between TRAF2 and SHARPIN
suggested by yeast two-hybrid screen implicates where
SHARPIN may act in the NF-kB pathway (UCSD Nature
Signaling Gateway).
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Figure 1. Top 10 canonical pathways. NF-kB signaling was a highly
associated pathway in the skin of Sharpincpdm/Sharpincpdm mutant mice based
on Ingenuity Pathway Analysis software. CPDM, chronic proliferative
dermatitis mutation; Sharpin, SHANK-associated RH domain interacting
protein.
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Improved Sharpincpdm/Sharpincpdm-mutant skin lesions in
Il1raptm1Roml/Il1raptm1Roml, Sharpincpdm/Sharpincpdm
compound mutants
Among 11 IL1 members, IL1F6, IL1F8, and IL1F9, which
activate NF-kB in an IL1 receptor accessory protein (IL1RAP)-
dependent manner (Barksby et al., 2007), are most signifi-
cantly upregulated. Therefore, loss of the IL1RAP should
abrogate IL1 signaling. To test this hypothesis C57BL/KaLa-
wRijSunJ-Sharpincpdm/Sharpincpdm male mice were crossed
with B6;129S1-Il1raptm1Roml/Il1raptm1Roml/J female mice.
Figure 2. Activation of NF-jB signaling in the skin of Sharpincpdm/Sharpincpdm mutant mice. Pathway analysis of transcriptome data in skin using Ingenuity
Pathway Analysis software suggested activation of both classical and alternative NF-kB pathways. Most of the molecules in NF-kB pathways were upregulated,
such as p65/RELA and NF-kB p52/RELB, in the mutant group from the pooled expression data of 2-, 4-, 6-, 8-, and 10-week-old mice. , upregulation; ,
downregulation; &, no significant change; CPDM, chronic proliferative dermatitis mutation; Sharpin, SHANK-associated RH domain interacting protein.
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A total of 8 Il1raptm1Roml/Il1raptm1Roml, Sharpincpdm/Shar-
pincpdm; 13 þ /Il1raptm1Roml, Sharpincpdm/Sharpincpdm; and
7 þ /þ , Sharpincpdm/Sharpincpdm F2 female progeny were
evaluated at 10 weeks of age (Figure 4a and b). The skin
lesions were significantly reduced in Il1raptm1Roml/
Il1raptm1Roml, Sharpincpdm/Sharpincpdm compound mutants
that had mild alopecia and scaling. Histology revealed
decreased severity of the skin lesions but not total resolution
of diseases (Figure 4c and d), as demonstrated by epidermal
thickness (Figure 4e; Po0.0001). þ /Il1raptm1Rom,
Sharpincpdm/Sharpincpdm- and þ /þ , Sharpincpdm/Sharpincpdm-
mutant mice were similarly affected. Numerous phosphory-
lated NF-kB p65-positive cells were still present in skin of the
compound mutants (Figure 3c), but were decreased compared
with that of þ /þ , Sharpincpdm/Sharpincpdm-mutant mice
(Figure 3d), indicating that other stimuli, beyond IL1RAP
modulation, contribute to NF-kB activation and in turn the skin
phenotype.
Bortezomib alleviates inflammation in Sharpincpdm/
Sharpincpdm-mutant mice by blocking NF-jB activation
Bortezomib inhibits IkB degradation, thereby preventing
translocation of NF-kB into the nucleus (Ma and Adjei,
2009). To test whether inhibition of this pathway would
improve the disease in Sharpincpdm/Sharpincpdm-mutant mice,
0.5mg kg1 of bortezomib was injected intraperitoneally
twice a week for 6 weeks into mutant and þ /þ control
mice, with equal volumes of physiological saline used as a
treatment control. Macroscopically, Sharpincpdm/Sharpincpdm
mice treated with bortezomib looked similar to þ /þ control
mice, except for small body size. As shown in Figure 5,
although mildly hyperplastic compared with the wild-type
control, skin from bortezomib-treated mice was significantly
(Po0.0001) reduced in thickness compared with the
vehicle-treated Sharpincpdm-mutant mice. NF-kB p65
phosphorylation was inhibited by bortezomib in the skin of
Sharpincpdm/Sharpincpdm mice (Figure 3e) and was close to
that of the þ /þ controls (Figure 3f), implicating the drug
effect on blockage of NF-kB activation, leading to reduction
in the severity of the skin phenotype. NF-kB p65 phosphor-
ylation in the þ /þ controls was not obviously affected by
administration of bortezomib, which might be due to a
feedback mechanism for NF-kB’s role in the physiological
function of skin (Kaufman and Fuchs, 2000; Gilmore, 2006;
Kim et al., 2009). Hypereosinophilia and the damage in other
organs were still present in Sharpincpdm/Sharpincpdm-mutant
mice (data not shown).
DISCUSSION
We show here that SHARPIN negatively regulates proin-
flammatory NF-kB signaling, primarily through the IL1
pathway in the skin of Sharpincpdm/Sharpincpdm-mutant mice.
Bortezomib treatment reduces the severity of the skin disease
and improves survival in a mouse model mimicking IHES
caused by loss of function of SHARPIN.
Human HES is a relatively rare syndrome with a
heterogeneous set of symptoms presumably due to multiple
etiologies (Roufosse et al., 2007; Kahn et al., 2008).
Unmasking the molecular basis for such diseases has led to
the development of semi-molecular classification schemes for
categorizing patients on the basis of recurrent genetic
alterations (Gotlib, 2008). Except for a transgenic mouse
model expressing the fusion gene FIP1-like 1/platelet-derived
growth factor receptor-a (FIP1L1/PDGFRA, F/P), no other
animal models have been reported to date for HES (Yamada
et al., 2008). The vast majority of HES cases are neither
associated with mutations in hematopoiesis nor lymphoid
clones. Analytical parameters cannot be simply converted
from humans to mice or vice versa (Sundberg and King,
1996). However, the peripheral blood eosinophil counts in
Figure 3. NF-jB p65 phosphorylation. NF-kB p65 was overphosphorylated in the skin of Sharpincpdm/Sharpincpdm mutant mice (arrows indicated positive,
brown, nuclei). NF-kB p65 phosphorylation was decreased by inactivation of Il1rap and, especially, by bortezomib inhibition in Sharpincpdm/Sharpincpdm-
mutant mice. Bortezomib did not affect NF-kB p65 phosphorylation in skin of control mice. (a) Sharpincpdm/Sharpincpdm-mutant mice; (b) þ /þ control;
(c) l1raptm1Roml/Il1raptm1Roml; (d) l1rapþ /l1rapþ , Sharpincpdm/Sharpincpdm-mutant mice; (e) Sharpincpdm/Sharpincpdm-mutant mice with bortezomib treatment;
(f) þ /þ control with bortezomib treatment. Bar¼ 5 mm. CPDM, chronic proliferative dermatitis mutation; Sharpin, SHANK-associated RH domain
interacting protein.
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wild-type C57BL/KaLawRijSunJ mice were 0.17109
cells per l, whereas that of healthy human is B0.35109
cells per l, which suggests that the diagnostic threshold of
HES (1.5109 eosinophils per l) can be used as one criteria
for identification of an HES model in mice (Kahn et al., 2008).
On the basis of the diagnostic criteria for HES in humans,
Sharpincpdm/Sharpincpdm-mutant mice could be a sponta-
neous mouse model for one type of HES, considering
eosinophil associated with multiorgan damage and persistent
eosinophilia (2.02109 cells per l). Simon and Simon (2007)
proposed a new classification of eosinophilic disorders based
on the primary cause as mutations in stem cells or cytokines
secreted by T cells or tumor cells. Alternatively, there could
be mutations in stem cells, leading to the clonal expansion of
T cells that can secrete cytokines inducing eosinophilia.
There are some human HES cases showing aberrant T-cell
phenotypes such as elevated CD3CD4þ T cells and
CD3þCD4CD8 T cells (Cogan et al., 1994; Simon et al.,
1999; Roufosse et al., 2004). These T cells have been shown
to produce Th2 cytokines: IL5, responsible for eosinophil
differentiation, maturation, activation, and prolonged survival
in the periphery, and IL4, which induces B-cell class-
switching leading to IgE production, a common feature of
the lymphocytic variant of HES. Although insignificant
numbers of CD3CD4þ were detected in Sharpincpdm/
Sharpincpdm-mutant mice, FACS data presented here indi-
cated that at least two lymphocyte subpopulations,
CD3þCD4CD8 T cells and B-1B cells, are abnormally
expanded in Sharpincpdm/Sharpincpdm-mutant mice. In con-
trast to the predominant population of B-2 B cells produced
in the bone marrow, B-1 B cells are a minor population of B
lymphocytes that are found in multiple tissues in the response
to bacteria and self-antigens, and participate in T-cell-
mediated alloimmune response (Montecino-Rodriguez and
Dorshkind, 2006; Nogueira-Martins and Mariano, 2009).
Significant increases of B-1 B cells in Sharpincpdm/Shar-
pincpdm-mutant mice may be partially related to the down-
regulation of sialic acid-binding Ig-like lectin G (Siglecg)
(transcriptome profiling data using spleen, not shown here),
which limits the expansion of B-1 B cells by downregulating
NF-kB activation (Ding et al., 2007). Significant increases of
B-1 B cells in mutant mice provide a tool to study its
biological function.
As described above, Sharpincpdm/Sharpincpdm-mutant mice
present a very complicated disorder including chronic
inflammation, proliferation, apoptosis, immune response,
and organ development abnormities (HogenEsch et al.,
1993, 1999; Seymour et al., 2006), all of which implicate
that Sharpin has diverse roles in crucial transduction
signaling or pathways. Pathway analysis by gene expression
profiling in skin revealed the constitutive activation of NF-kB
signaling in the skin of Sharpincpdm/Sharpincpdm-mutant mice,
as disease developed predominantly through IL1 cascades.
IL1 family members are known to alter the host response to
an inflammatory, infectious, or immunological challenge
(Dinarello, 2009). The IL1 family comprises 11 ligands (IL1F1
to IL1F11) and 3 receptors (IL1RI, Il1RAP, and IL1RII)
(Boraschi and Tagliabue, 2006; Barksby et al., 2007).
Although other IL1 family members also showed upregulation
at the mRNA level in skin of Sharpincpdm/Sharpincpdm-mutant
mice, IL1F6, IL1F8, and IL1F9 were the most significantly
elevated, suggesting the importance of this subfamily in skin
inflammation. IL1F6, IL1F8, and IL1F9 activate pathways
leading to NF-kB and mitogen-activated protein
kinase signaling in an IL1RAP- and IL1Rrp2-dependent
manner (Towne et al., 2004). IL1F6 transgenic mice exhibit
II1rap –/–Sharpincpdm mice II1rap+/+Sharpincpdm mutants
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Figure 4. Lack of Il1rap improved the skin disease in Sharpincpdm/
Sharpincpdm-mutant mice. Loss of Il1rap in Sharpincpdm/Sharpincpdm-mutant
mice resulted in mice appearing clinically normal (a, c) compared with
Il1rapþ /þ , Sharpincpdm/Sharpincpdm-mutant mice (b, d). Histology revealed
decreased severity of the skin lesions but not total resolution of diseases, as
shown by epidermal thickness (e—1 represents þ /þ , Sharpincpdm/
Sharpincpdm; 2 represents l1raptm1Roml/Il1raptm1Roml, Sharpincpdm/Sharpincpdm;
3 represents l1raptm1Roml/Il1raptm1Roml,þ /þ ; and 4 represents þ /þ , þ /þ ).
Note: size of PCR products: Il1rap band (168 bp), Neo (280 bp).
Bar ¼5 mm. CPDM, chronic proliferative dermatitis mutation; Il1rap,
IL1 receptor accessory protein; Sharpin, SHANK-associated RH domain
interacting protein.
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psoriasiform skin abnormalities that are dependent on
IL1RRP2 and IL1RAP (Blumberg et al., 2007). Furthermore,
expression of IL1F2 was also increased in psoriasiform skin
lesions in flaky skin (Ttc7fsn/Ttc7fsn) mice (Schon et al., 2001).
The skin disease improved in the compound mutant
Il1raptm1Roml/Il1raptm1Roml, Sharpincpdm/Sharpincpdm mice,
suggesting that IL1RAP-dependent signals induced by IL1F6,
IL1F8, and IL1F9 have major roles in the development of skin
damage in these mice.
NF-kB transduction pathways can be activated by many
diverse stimuli such as TNF and lipopolysaccharide in
addition to IL1 family members. Proteasome inhibition,
blockading a common link of the complicated NF-kB
circuit using bortezomib, reduced skin lesion severity in
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Figure 5. NF-jB inhibition by bortezomib treatment reduced the skin problem in Sharpincpdm/Sharpincpdm-mutant mice. (a, e) Bortezomib-treated
Sharpincpdm/Sharpincpdm-mutant mice. Alopecia on the dorsal skin with partial histological resolution. Histologically, skin lesions were improved, but still
present with moderate acanthosis and mild orthokeratotic hyperkeratosis. (b, f) Bortezomib-treated þ /þ controls. No skin lesions. Normal skin histology.
(c, g) Saline-treated Sharpincpdm/Sharpincpdm-mutant mice. Severe scaling, alopecia, and ulcers on the dorsal skin. Marked acanthosis, orthokeratotic
hyperkeratosis, apoptosis, and granulocytic infiltration in the dermis. (d, h) Saline-treated þ /þ controls. No skin lesions. Normal skin histology.
(i) Measurement of epidermal thickness. Bar ¼ 5mm. CPDM, chronic proliferative dermatitis mutation; Sharpin, SHANK-associated RH domain
interacting protein.
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Sharpincpdm/Sharpincpdm-mutant mice. Through reversible
inhibition of this major proteolytic system, bortezomib
potentially interacts with multiple signaling pathways critical
for inflammation, tumor cell growth, survival, and apoptosis
(Adams et al., 1999; Dicato et al., 2006). Bortezomib blocks
proliferation and induces apoptosis, and was approved by
United States Food and Drug Administration for initial
treatment of patients with multiple myeloma (Curran and
McKeage, 2009; Ma and Adjei, 2009). This agent also inhibits
the proteasomal degradation of NF-kBIA, downregulating
inducible NF-kB signaling. Macroscopic and microscopic
observations indicated that bortezomib administration
resulted in a moderate improvement in the skin phenotype
in Sharpincpdm/Sharpincpdm-mutant mice, again suggesting
that SHARPIN has a critical role in regulating proinflamma-
tory NF-kB signaling in the skin. Regarding the therapeutic
effect on dermatitis, steroids, the primary treatment of the
FIP1L1/PDGFRA-negative form of HES, were also shown to
have moderate effects on dermatitis in Sharpincpdm/
Sharpincpdm-mutant mice (Gijbels et al., 2000). Moreover,
treatment with recombinant IL12 resulted in almost complete
resolution of the skin disease in Sharpincpdm/Sharpincpdm-
mutant mice (HogenEsch et al., 2001), which implied that
some Th2 cytokines can cause dermatitis in an NF-kB-
independent manner. The dissociation between eosinophilia
and the clinical effect of bortezomib is consistent with a
previous report that anti-IL5 decreases the absolute eosino-
phil count in peripheral blood but not the severity of
dermatitis in Sharpincpdm/Sharpincpdm mice (Renninger
et al., 2009), indicating that infiltration of eosinophils into
skin may be a secondary event to NF-kB activation and has
both proinflammatory and antiinflammatory roles in the
development of dermatitis of these mice. Although eosino-
philia is the hallmark of human hypereosinophilic diseases,
the relationship between the absolute eosinophil count and
end-organ damage in this syndrome is inconsistent (Plotz
et al., 2003; Boucher et al., 2008). Clinical trials in humans
demonstrated that anti-IL5 therapy results in a rapid decrease
in peripheral blood eosinophil numbers. Moreover, improve-
ment of symptoms in human patients with lymphocytic
variants of HESs, eosinophilic esophagitis, and chronic
rhinitis with nasal polyposis, were observed with anti-IL5
therapy. In contrast, in HES patients with bronchial asthma or
atopic eczema, anti-IL5 therapy showed only moderate or no
clinical effects (Simon et al., 2007). Future studies will have
to identify those eosinophilic diseases in which anti-IL5
antibodies are effective.
In conclusion, this study identified a mouse model
mimicking IHES, with eosinophilic dermatitis caused by loss
of function of SHARPIN, which negatively regulates proin-
flammatory NF-kB signaling primarily in the IL1 pathway in
the skin. Bortezomib has therapeutic benefits in these mutant
mice, suggesting potential value for IHES patients.
MATERIALS AND METHODS
Mice
C57BL/KaLawRij-Sharpincpdm/RijSunJ (JR no. 007599), C57BL/KaLa-
wRijSunJ þ /þ , and B6;129S1-Il1raptm1Roml/J (JR no. 003284) mice
were maintained in a humidity-, temperature-, and light cycle
(12:12)-controlled vivarium under specific pathogen-free conditions
(The Jackson Laboratory, http://jaxmice.jax.org). Sharpincpdm/Shar-
pincpdm-mutant mice of both sexes are equally affected. As female
mutant mice do not breed, they were used for all experiments unless
indicated otherwise. Mice were housed in double-pen polycarbo-
nate cages at a maximum capacity of four mice per pen. Mice were
allowed free access to autoclaved food (NIH 31, 6% fat; LabDiet
5K52, Purina Mills, St. Louis, MO) and acidified water (pH 2.8–3.2).
All work was done with Institutional Animal Care and Use
Committee approval.
Antibodies
The fluorochrome-conjugated mAb to mouse antigens used for flow
cytometry were purchased from BD Bioscience (San Diego, CA):
anti-CD2 FITC (RM2-S), anti-CD3e PC7 (KT31.1), anti-CD4 APC
(RM4-5), anti-CD8 biotin (YTS 169.4), anti-CD25 PE (PC61), anti-
CD95 PE (JO2), anti-FOXP3 APC (259D/C7), CD45R/B220 biotin
(RA3-6B2), CD11b/MAC-1 PE (M1/70), CD11c FITC (N418), and
GR-1/LY6G AC7 (RB6-8C5). The phosphorylated NF-kB p65 anti-
body was obtained from Cell Signaling (Danvers, MA).
Complete blood counts
Whole blood (275ml) was drawn from the retro-orbital sinus through
EDTA-coated microhematocrit tubes directly into Eppendorf tubes
containing 30 ml 20% EDTA in PBS. The additional anticoagulant is
critical in preventing microclot formation. Complete blood counts
were determined immediately after obtaining the samples using an
Advia 120 Multispecies whole blood analyzer (Bayer Corporation,
Tarrytown, NY). Three Sharpincpdm-mutant and three þ /þ control
mice were used for each time point.
Flow cytometric analysis
Splenocytes were harvested from mice according to protocol
A (http://openwetware.org/wiki/Isolation_of_murine_splenocytes).
Cells were then incubated with various combinations of mAb for
25minutes at 4 1C, washed twice with FACS buffer, and fixed with
1% paraformaldehyde. Flow cytometric analysis was performed by
using conventional multiparameter procedures. Analysis was carried
out on a FACScan (Becton Dickinson, Franklin Lakes, NJ), with
CELLQuest software (Becton Dickinson) for acquisition and FlowJo
software (Tree Star, Ashland, OR) for analysis. Viable cells were
gated by propidium iodide exclusion.
Transcriptional profiling and pathway analysis
RNA isolation, cDNA preparation, and microarray hybridi-
zation. Dorsal interscapular thoracic skin and spleen were
collected from three Sharpincpdm/Sharpincpdm and three þ /þ
female mice at 2, 4, 6, 8, and 10 weeks of age to provide a cross-
sectional transcription profile to determine the molecular pathogen-
esis of the disease. Total RNA was isolated by TRIzolPlus kit
(Invitrogen, Carlsbad, CA) according to the manufacturer’s protocols.
cDNA was then hybridized onto GeneChip Mouse Gene 1.0 ST
Arrays (Affymetrix, Santa Clara, CA). Raw intensity values were
normalized to positive control genes and each gene was normalized
to the age-matched control. The fold change of the hybridization
intensity of samples was used to represent the relative gene
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expression level. Data were analyzed through the use of Ingenuity
Pathways Analysis (Ingenuity).
Bortezomib administration
Lyophilized bortezomib was obtained from L.C. laboratories
(Velcade, Woburn, MA). Stock bortezomib solution (5mgml1)
was prepared in physiological saline (Hospira, Lake Forest, IL) and
stored at 20 1C. The stocks were diluted in physiological saline
immediately before use.
Groups of 4-week-old, female Sharpincpdm/Sharpincpdm or þ /þ
mice (N¼ 10 mice per group) were injected intraperitoneally with
0.5mg kg1 body weight of bortezomib or an equivalent volume of
physiological saline twice weekly for 6 weeks. Body weights and
gross photos were obtained before every injection and at the time of
necropsy. Complete blood cell counts were evaluated 3 days after
the last injection. A complete necropsy was performed on each
mouse (Seymour et al., 2004). Spleen, liver, brain, and kidneys were
weighed at the time of necropsy. Tissues were processed routinely,
paraffin-embedded, sectioned at 6 mm, and stained with hematoxylin
and eosin. Histology was evaluated by an experienced veterinary
pathologist (JPS).
Creation of Il1rap-Sharpin compound mutant mice
Il1raptm1Roml targeted mutant mice with a selectable Neo cassette were
obtained from The Jackson Laboratory (B6;129S1-Il1raptm1Roml/J).
Homozygous B6;129S1-Il1raptm1Roml/J females were crossed with
homozygous C57BL/KaLawRij-Sharpincpdm/RijSun males. Phenotypes
of 10-week-old, female F2 progeny were compared between groups of
each genotype (Il1raptm1Roml/Il1raptm1Roml, Sharpincpdm/Sharpincpdm;
þ /Il1raptm1Roml, Sharpincpdm/Sharpincpdm; þ /þ , Sharpincpdm/Shar-
pincpdm). Sharpin genotypes were identified by direct sequencing for
PCR products amplified with primers shown below: 50-TGTGT
TTGTGTGCATTGGTG-30 (forward) and 50-CCCACGGACGGTGTAA
CAAA-30 (reverse). Primer pairs for both Neo and Il1rap were included
in the same PCR reaction to determine Il1rap deletion. Primers for
Il1rap fragment were: 50-ACTACAGCACTGCCCATTCC-30 (forward)
and 50-TGTAATTGCCCGTGTCATTG-30 (reverse). Primers for
Neo fragment were: 50-CTTGGGTGGAGAGGCTATTC-30 (forward)
and 50-AGGTGAGATGACAGGAGATC-30 (reverse). Il1rapþ /þ , þ /
Il1raptm1Roml, and Il1raptm1Roml/Il1raptm1Roml were identified by the
presence of only the Il1rap band (168bp), bothNeo (280bp) and Il1rap
(168bp) bands, and only the Neo band (280bp), respectively.
Immunohistochemistry
Dorsal skin was collected and fixed by immersion in Fekete’s acid
alcohol formalin solution and then transferred after 12 hours into
70% ethanol until processed (Mikaelian et al., 2004). Fixed tissues
were embedded routinely in paraffin and serially sectioned at 6 mm.
Paraffin sections were stained at 1:50 dilutions for phosphorylated
NF-kB p65 (Ser276, Cell Signaling, Danvers, MA).
Measurement of epidermal thickness
Epidermal thickness of 10 fields for each sample, one sample per
mouse, and three mice per group was measured. Every field
included at least one full-length hair follicle as an internal standard
for orientation. The epidermal thickness was measured from the
basement membrane to the top of the stratum granulosum.
Statistical analysis
Data were expressed as mean±SE. Statistical comparisons between
two groups were performed by the Student’s t-test. Statistical
significance was determined as Po0.05.
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